Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series.
CLN2 disease
atypical
cerliponase alfa
late infantile neuronal ceroid lipofuscinosis
natural history
neuronal ceroid lipofuscinosis type 2
Journal
Journal of child neurology
ISSN: 1708-8283
Titre abrégé: J Child Neurol
Pays: United States
ID NLM: 8606714
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
pubmed:
29
12
2020
medline:
15
12
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
The classic phenotype of CLN2 disease (neuronal ceroid lipofuscinosis type 2) typically manifests between ages 2 and 4 years with a predictable clinical course marked by epilepsy, language developmental delay, and rapid psychomotor decline. Atypical phenotypes exhibit variable time of onset, symptomatology, and/or progression. Intracerebroventricular-administered cerliponase alfa (rhTPP1 enzyme) has been shown to stabilize motor and language function loss in patients with classic CLN2 disease, but its impact on individuals with atypical phenotypes has not been described. A chart review was conducted of 14 patients (8 male, 6 female) with atypical CLN2 phenotypes who received cerliponase alfa. Pre- and posttreatment CLN2 Clinical Rating Scale Motor and Language (ML) domain scores were compared. Median age at first presenting symptom was 5.9 years. First reported symptoms were language abnormalities (6 [43%] patients), seizures (4 [29%]), ataxia/language abnormalities (3 [21%]), and ataxia alone (1 [7%]). Median age at diagnosis was 10.8 years. ML score declined before treatment in 13 (93%) patients. Median age at treatment initiation was 11.7 years; treatment duration ranged from 11 to 58 months. From treatment start, ML score remained stable in 11 patients (treatment duration 11-43 months), improved 1 point in 1 patient after 13 months, and declined 1 point in 2 patients after 15 and 58 months, respectively. There were 13 device-related infections in 8 patients (57%) and 10 hypersensitivity reactions in 6 (43%). Cerliponase alfa is well tolerated and has the potential to stabilize motor and language function in patients with atypical phenotypes of CLN2 disease.
Sections du résumé
BACKGROUND
The classic phenotype of CLN2 disease (neuronal ceroid lipofuscinosis type 2) typically manifests between ages 2 and 4 years with a predictable clinical course marked by epilepsy, language developmental delay, and rapid psychomotor decline. Atypical phenotypes exhibit variable time of onset, symptomatology, and/or progression. Intracerebroventricular-administered cerliponase alfa (rhTPP1 enzyme) has been shown to stabilize motor and language function loss in patients with classic CLN2 disease, but its impact on individuals with atypical phenotypes has not been described.
METHODS
A chart review was conducted of 14 patients (8 male, 6 female) with atypical CLN2 phenotypes who received cerliponase alfa. Pre- and posttreatment CLN2 Clinical Rating Scale Motor and Language (ML) domain scores were compared.
RESULTS
Median age at first presenting symptom was 5.9 years. First reported symptoms were language abnormalities (6 [43%] patients), seizures (4 [29%]), ataxia/language abnormalities (3 [21%]), and ataxia alone (1 [7%]). Median age at diagnosis was 10.8 years. ML score declined before treatment in 13 (93%) patients. Median age at treatment initiation was 11.7 years; treatment duration ranged from 11 to 58 months. From treatment start, ML score remained stable in 11 patients (treatment duration 11-43 months), improved 1 point in 1 patient after 13 months, and declined 1 point in 2 patients after 15 and 58 months, respectively. There were 13 device-related infections in 8 patients (57%) and 10 hypersensitivity reactions in 6 (43%).
CONCLUSIONS
Cerliponase alfa is well tolerated and has the potential to stabilize motor and language function in patients with atypical phenotypes of CLN2 disease.
Identifiants
pubmed: 33356800
doi: 10.1177/0883073820977997
pmc: PMC8027928
doi:
Substances chimiques
Recombinant Proteins
0
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
EC 3.4.14.-
cerliponase alfa
EC 3.4.14.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
468-474Références
Mol Genet Metab. 1999 Apr;66(4):339-43
pubmed: 10191126
Genet Med. 2000 Nov-Dec;2(6):312-8
pubmed: 11339651
J Am Acad Dermatol. 2007 Oct;57(4):722-4
pubmed: 17870436
J Neurol. 2003 Jun;250(6):661-7
pubmed: 12796825
J Neurol Sci. 2015 Sep 15;356(1-2):65-71
pubmed: 26143525
Mol Genet Metab. 1999 Apr;66(4):248-52
pubmed: 10191110
Am J Med Genet. 2002 Nov 1;112(4):347-54
pubmed: 12376936
Mol Genet Metab. 1999 Jun;67(2):162-8
pubmed: 10356316
Acta Neuropathol. 2008 Jul;116(1):119-24
pubmed: 18283468
Mol Genet Metab. 2008 Jan;93(1):66-73
pubmed: 17959406
Gene. 2013 Mar 1;516(1):114-21
pubmed: 23266810
J Med Genet. 2002 Nov;39(11):822-5
pubmed: 12414822
J Med Genet. 2004 Nov;41(11):858-66
pubmed: 15520412
Hum Mutat. 2013 May;34(5):706-13
pubmed: 23418007
N Engl J Med. 2018 May 17;378(20):1898-1907
pubmed: 29688815
F1000Res. 2018 Dec 19;7:
pubmed: 30613388
Biochim Biophys Acta. 2013 Nov;1832(11):1801-6
pubmed: 23602993
Lancet Neurol. 2019 Jan;18(1):107-116
pubmed: 30470609
Seizure. 2019 Jul;69:180-185
pubmed: 31059981
Neuropediatrics. 1997 Feb;28(1):6-8
pubmed: 9151309
Neurogenetics. 2013 Nov;14(3-4):225-32
pubmed: 24091540
Am J Hum Genet. 1999 Jun;64(6):1511-23
pubmed: 10330339
Neurology. 2015 Oct 6;85(14):1259-61
pubmed: 26224725
Lancet Child Adolesc Health. 2018 Aug;2(8):582-590
pubmed: 30119717
Science. 1997 Sep 19;277(5333):1802-5
pubmed: 9295267
Am J Med Genet. 1992 Feb 15;42(4):536-8
pubmed: 1609834
Pediatr Neurol. 2016 Jul;60:75-8
pubmed: 27343025
Clin Genet. 2008 Sep;74(3):213-22
pubmed: 18684116
Hum Mutat. 2019 Nov;40(11):1924-1938
pubmed: 31283065